Europe’s pharmaceutical sector could lose out to increased competition from emerging markets, China and the U.S. in terms of research and innovation if a proposed European Union health package is not amended, its key industry group said on Thursday.
Life sciences–focused venture capital firm Flagship Pioneering unveiled its newest start-up Wednesday: the Cambridge, Mass.–based Empress Therapeutics, which aims to speed up the identification and development of small molecule drugs.
PTC Therapeutics said on Wednesday its experimental Huntington’s disease drug lowered mutated protein levels that cause the neurological disease, citing interim data from a mid-stage study.
Following the death of a patient, the FDA has placed a clinical hold on Arcellx’s iMMagine-1 Phase II trial of its T cell therapy for relapsed or refractory multiple myeloma. The company’s stock fell around 23% in pre-market trading Tuesday.
Merck & Co. said on Tuesday its blockbuster immunotherapy Keytruda failed to meet one of the two main goals in a late-stage study testing it as a treatment option for a type of advanced gastric cancer.
Eli Lilly and Co. agreed to buy Dice Therapeutics Inc. for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer.
Belgium-based BioSenic is suspending the development of ALLOB, an investigational allogeneic cell therapy derived from mesenchymal stem cells, which was being assessed as a treatment for tibial fractures, the company announced Monday.
Eli Lilly’s head-to-head CHALLENGE-MIG trial missed its primary endpoint Friday, failing to establish the statistical superiority of the company’s Emgality (galcanezumab-gnlm) over Pfizer’s Nurtec orally disintegrating tablets (rimegepant).
The Bespoke Gene Therapy Consortium, managed by the Foundation for the National Institutes of Health, aims to accelerate the development process for gene therapies targeting rare diseases—conditions for which there are currently few therapeutic options. The public-private partnership selected the first eight rare diseases in May for its clinical trials program.
Coherus Biosciences announced plans Friday to acquire Surface Oncology, a clinical-stage immuno-oncology company, in a deal worth up to $65 million. The acquisition aims to bolster Coherus’ position in cancer therapeutics and expand its product portfolio.
